Citadel Advisors
LNAI

Citadel Advisors’s Lunai Bioworks LNAI Stock Holding History

Citadel Advisors’s Portfolio LNAI Stock Details LNAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-140
Closed -$3.24K – 13871
2025
Q2 		$3.24K Buy
140
+40
+40% +$1.12K ﹤0.01% 12250
2025
Q1 		$4.35K Buy
100
+46
+85% +$2.94K ﹤0.01% 13898
2024
Q4 		$3.59K Sell
54
-55
-50% -$3.65K ﹤0.01% 13986
2024
Q3 		$4.21K Buy
+109
New +$7.56K ﹤0.01% 13590
2023
Q4 		– Sell
-46
Closed -$16.5K – 15085
2023
Q3 		$16.5K Sell
46
-103
-69% -$15.7K ﹤0.01% 12775
2023
Q2 		$6.74K Buy
+149
New +$11.4K ﹤0.01% 13403
2023
Q1 		– Sell
-158
Closed -$13K – 15381
2022
Q4 		$13K Buy
+158
New +$21.2K ﹤0.01% 13475
2022
Q3 		– Sell
-174
Closed -$27K – 13443
2022
Q2 		$27K Buy
174
+46
+36% +$21K ﹤0.01% 12280
2022
Q1 		$84K Buy
+128
New +$68.2K ﹤0.01% 12439

Other funds holding LNAI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's LNAI Position: Q1 2026 in Review

Citadel Advisors sold out of Lunai Bioworks (LNAI) in Q1 2026, closing a stake of 2,579 shares — an estimated $18.2K sold.

Citadel Advisors first reported a position in LNAI in Q1 2021 and held it in 9 quarters. The position peaked at $476K in Q1 2022. 27 funds tracked by Wall St. Rank hold LNAI as of Q1 2026.

  • Citadel Advisors reported no remaining Lunai Bioworks position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 2,579 Lunai Bioworks shares in Q1 2026, an estimated $18.2K.
  • Citadel Advisors first reported a position in Lunai Bioworks in Q1 2021 and held it in 9 quarters.
  • Citadel Advisors's Lunai Bioworks position peaked at $476K in Q1 2022.
  • 27 funds tracked by Wall St. Rank held Lunai Bioworks as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.